Clinical Trials · NCT00781911
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 43
- Start date
- Feb 2009
- Locations
- 10 sites, United States
- Primary endpoint
- Percentage of Participants With Progression-Free Survival (PFS) Rate at Six Months